Newland Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Equivalents	123.89	169	281.58	270.02	51.13	34.21
Trading Asset Securities	542.35	549.55	525.16	589.5	701.36	8.67
Cash & Short-Term Investments	666.23	718.55	806.75	859.52	752.49	42.88
Cash Growth	-15.40%	-10.93%	-6.14%	14.22%	1654.94%	17.63%
Accounts Receivable	368.82	270.55	332.61	240.9	360.46	269.6
Other Receivables	0.19	0.03	0.06	0.19	0.26	0.16
Receivables	369.01	270.58	332.67	241.09	360.72	269.76
Inventory	66.35	72.37	45.06	31	53.52	78.57
Other Current Assets	4.21	5.18	10.55	25.04	20.38	9.8
Total Current Assets	1,106	1,067	1,195	1,157	1,187	401
Property, Plant & Equipment	648.08	659.65	574.78	388.2	295.52	225.67
Other Intangible Assets	49.52	49.99	36.82	38.08	38.77	39.71
Long-Term Deferred Tax Assets	-	-	-	-	-	1.01
Long-Term Deferred Charges	0.92	1.34	3.38	5.61	1.29	-
Other Long-Term Assets	18.29	1.85	3.73	20.96	11.08	0.51
Total Assets	1,823	1,780	1,814	1,610	1,534	667.9
Accounts Payable	105.51	97.68	138.66	87.75	106.37	80.26
Accrued Expenses	14.89	24.37	23.78	30.33	18.18	27.81
Short-Term Debt	0.47	-	0.73	-	-	91.33
Current Portion of Long-Term Debt	-	-	-	-	-	4.66
Current Portion of Leases	-	2.81	-	1.99	2.84	-
Current Income Taxes Payable	8.29	0.06	-	-	-	3.05
Current Unearned Revenue	4.47	3.28	5.32	4.43	4.61	1.68
Other Current Liabilities	40.48	42.17	48.3	14.96	24.01	11.8
Total Current Liabilities	174.11	170.35	216.78	139.47	156.01	220.58
Long-Term Debt	-	-	-	-	-	30.39
Long-Term Leases	1.39	2.89	2.25	0.73	2.88	-
Long-Term Unearned Revenue	50.13	44.23	41.88	10.04	10.3	10.56
Long-Term Deferred Tax Liabilities	10.5	11.02	9.77	9.78	5.39	-
Total Liabilities	236.14	228.49	270.69	160.02	174.58	261.53
Common Stock	392.08	392.08	280.06	200.04	133.36	100
Additional Paid-In Capital	532.74	532.74	644.77	724.78	791.46	5.49
Retained Earnings	656.03	619.93	610.7	517.09	424.79	292.48
Comprehensive Income & Other	6.28	6.59	6.67	6.11	6.33	4.56
Total Common Equity	1,587	1,551	1,542	1,448	1,356	402.53
Minority Interest	-0.65	-0.33	0.85	1.47	3.25	3.85
Shareholders' Equity	1,586	1,551	1,543	1,449	1,359	406.38
Total Liabilities & Equity	1,823	1,780	1,814	1,610	1,534	667.9
Total Debt	1.86	5.69	2.98	2.72	5.72	126.38
Net Cash (Debt)	664.37	712.86	803.77	856.8	746.77	-83.5
Net Cash Growth	-15.10%	-11.31%	-6.19%	14.73%	-	-
Net Cash Per Share	1.70	1.82	2.04	2.19	2.48	-0.28
Filing Date Shares Outstanding	391.97	392.08	392.08	392.08	392.08	294
Total Common Shares Outstanding	391.97	392.08	392.08	392.08	392.08	294
Working Capital	931.71	896.33	978.24	1,017	1,031	180.43
Book Value Per Share	4.05	3.96	3.93	3.69	3.46	1.37
Tangible Book Value	1,538	1,501	1,505	1,410	1,317	362.82
Tangible Book Value Per Share	3.92	3.83	3.84	3.60	3.36	1.23
Buildings	-	380.5	211.94	169.21	151.69	148.36
Machinery	-	467.7	295.69	235.66	187.31	125.82
Construction In Progress	-	13.46	222.1	106.7	55.35	33.02

Source: S&P Global Market Intelligence. Standard template. Financial Sources.